A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections
Information source: Kaohsiung Medical University Chung-Ho Memorial Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Intra-abdominal Infection
Intervention: moxifloxacin (Drug); ampicillin/sulbactam (Drug)
Phase: Phase 4
Sponsored by: Kaohsiung Medical University Chung-Ho Memorial Hospital
On the basis of monotherapy for intra-abdominal infection, the investigators are conducting
this study to identify the difference of drug efficacy between ampicillin/sulbactam and
Official title: A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Primary outcome: clinical response at test-of-cure visit
Minimum age: N/A.
Maximum age: N/A.
- patients diagnosed of complicated intra-abdominal infection need surgical treatment
- patients diagnosed of intra-abdominal infection receive non-operative management
- patients with known allergic history of fluoroquinolone
- Severe, life threatening disease with a life expectancy of < 48 h or APS and APACHE
scores of > 35
Locations and Contacts
Kaohsiung Medical University Hospital, Department of Emergency Medicine/Surgery, Kaohsiung 804, Taiwan
Starting date: January 2009
Last updated: August 1, 2011